Document is current
Any future updates will be listed below
-
Authors
Xu, Rongbin http://orcid.org/0000-0003-1906-8614
Ye, Tingting http://orcid.org/0000-0001-5405-7051
Yue, Xu http://orcid.org/0000-0002-8861-8192
Yang, Zhengyu
Yu, Wenhua
Zhang, Yiwen
Bell, Michelle L. http://orcid.org/0000-0002-3965-1359
Morawska, Lidia http://orcid.org/0000-0002-0594-9683
Yu, Pei
Zhang, Yuxi
Wu, Yao http://orcid.org/0000-0002-8105-0522
Liu, Yanming
Johnston, Fay http://orcid.org/0000-0002-5150-8678
Lei, Yadong
Abramson, Michael J. http://orcid.org/0000-0002-9954-0538
Guo, Yuming http://orcid.org/0000-0002-1766-6592
Li, Shanshan http://orcid.org/0000-0002-9021-8470
- License Information
-
More Information
Article History
Received: 24 October 2022
Accepted: 3 July 2023
First Online: 20 September 2023
Competing interests
: Michael J. Abramson holds investigator-initiated grants from Pfizer, Boehringer-Ingelheim, Sanofi and GSK for unrelated research. He has undertaken an unrelated consultancy for Sanofi. He also received a speaker’s fee from GSK. The other authors declare no competing interests.
